Patents by Inventor Lloyd H. Waxman

Lloyd H. Waxman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein for inhibiting collagen-stimulated platelet aggregation
    Patent number: 5340726
    Abstract: A protein which inhibits collagen-stimulated platelet aggregation. The protein has a molecular weight of approximately 17,000. A method of isolating the protein from Ornithodoros moubata and using the protein to prevent or delay blood coagulation by blocking the stimulation of platelet aggregation by collagen is also described. The protein is useful in the prevention, prophylaxis, therapy and treatment of thrombotic diseases.
    Type: Grant
    Filed: August 16, 1993
    Date of Patent: August 23, 1994
    Assignee: Merck & Co., Inc.
    Inventors: Thomas M. Connolly, Paul M. Keller, Lloyd H. Waxman
  • Processes for making proteins having anticoagulant properties
    Patent number: 5328997
    Abstract: Proteins which specifically inhibit coagulation Factor Xa. The inhibitors, which do not inhibit Factor VIIa, kallikrein, trypsin, chymotrypsin, thrombin, urokinase, tissue plasminogen activator, plasmin, elastase, Factor XIa or S. aureus V8 protease, are polypeptides of 60 amino acid residues. The inhibitors may be purified from Ornithodoros moubata extract, synthesized, or produced using a recombinant DNA yeast expression system.
    Type: Grant
    Filed: April 28, 1993
    Date of Patent: July 12, 1994
    Assignee: Merck & Co., Inc.
    Inventors: George P. Vlasuk, Lloyd H. Waxman, Victor M. Garsky, Michael P. Neeper
  • Proteins having anticoagulant properties
    Patent number: 5239058
    Abstract: Proteins which specifically inhibit coagulation Factor Xa. The inhibitors, which do not inhibit Factor VIIa, kallikrein, trypsin, chymotrypsin, thrombin, urokinase, tissue plasminogen activator, plasmin, elastase, Factor XIa or S. aureus V8 protease, are polypeptides of 60 amino acid residues. The inhibitors may be purified from Ornithodoros moubata extract, synthesized, or produced using a recombinant DNA yeast expression system.
    Type: Grant
    Filed: April 29, 1992
    Date of Patent: August 24, 1993
    Assignee: Merck & Co., Inc.
    Inventors: George P. Vlasuk, Lloyd H. Waxman, Victor M. Garsky, Michael P. Neeper